Prostate Cancer - Results from #1140

Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer. March 28, 2024

A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer. March 28, 2024

Interaction of patient age and high-grade prostate cancer on targeted biopsies of MRI suspicious lesions. March 28, 2024

Patterns of B-cell lymphocyte expression changes in pre- and post-malignant prostate tissue are associated with prostate cancer progression. March 28, 2024

Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study. March 28, 2024

Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer. March 27, 2024

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient. March 27, 2024

A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1. March 27, 2024

Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer. March 27, 2024

Can we predict pathology without surgery? Weighing the added value of multiparametric MRI and whole prostate radiomics in integrative machine learning models. March 27, 2024

MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer. March 26, 2024

Variation in Access to Palliative Radiotherapy in Prostate Cancer: A Population-Based Study in Canada. March 26, 2024

A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer. March 26, 2024

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. March 26, 2024

Tissue-Based Genomic Testing in Prostate Cancer: 10-Year Analysis of National Trends on the Use of Prolaris, Decipher, ProMark, and Oncotype DX. March 26, 2024

RAPHIA: A deep learning pipeline for the registration of MRI and whole-mount histopathology images of the prostate. March 26, 2024

Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. March 26, 2024

Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. March 26, 2024

Gender-Based Disparity Exists in the Surgical Experience of Female and Male Urology Residents March 25, 2024

The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations. March 25, 2024

Page 58 of 1435